Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation

European Journal of Health Economics

Volumn 14, Issue 6, 2013, Pages 1035-1048

  Stollenwerk, Björn ^a,b   Gandjour, Afschin ^c   Lüngen, Markus ^d   Siebert, Uwe ^b,e,f,g  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^c FRANKFURT SCHOOL OF FINANCE AND MANAGEMENT   (Germany)

^d UNIVERSITY OF APPLIED SCIENCES OSNABRÜCK   (Germany)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g Oncotyrol Center for Personalized Cancer Medicine   (Austria)

Author keywords

Decision analytic modelling; Hazard ratio; Model; Mortality; Screening

Indexed keywords

ARTICLE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DISEASE SPECIFIC MORTALITY; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; MORTALITY; PARAMETRIC TEST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; MODELS, ECONOMIC; MORTALITY; RISK FACTORS;

EID: 84876308309     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0454-z     Document Type: Article

References (60)

1. Hayashino, Y.; Shimbo, T.; Tsujii, S.; Ishii, H.; Kondo, H.; Nakamura, T.; Nagata-Kobayashi, S.; Fukui, T.: Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing an international application of evidence-based guidelines. Int. J. Cardiol. 118(1), 88-96 (2007)
2. O'Malley, P.G.; Greenberg, B.A.; Taylor, A.J.: Cost-effectiveness of using electron beam computed tomography to identify patients at risk for clinical coronary artery disease. Am. Heart J. 148(1), 106-113 (2004)
3. Yang, K.C.; Liao, C.S.; Chiu, Y.H.; Yen, A.M.; Chen, T.H.: Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. J. Med. Screen. 13(Suppl 1), S8-S13 (2006)
4. Svatek, R.S.; Sagalowsky, A.I.; Lotan, Y.: Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol. Oncol. 24(4), 338-343 (2006)
5. Siebert, U.; Sroczynski, G.; Hillemanns, P.; Engel, J.; Stabenow, R.; Stegmaier, C.; Voigt, K.; Gibis, B.; Holzel, D.; Goldie, S.J.: The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur. J. Public Health 16(2), 185-192 (2006)
6. Mason, J.; Axon, A.T.; Forman, D.; Duffett, S.; Drummond, M.; Crocombe, W.; Feltbower, R.; Mason, S.; Brown, J.; Moayyedi, P.: The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment. Pharmacol. Ther. 16(3), 559-568 (2002)
7. Stein, K.; Dalziel, K.; Walker, A.; Jenkins, B.; Round, A.; Royle, P.: Screening for Hepatitis C in injecting drug users: a cost utility analysis. J. Public Health (Oxf) 26(1), 61-71 (2004)
8. Icks, A.; Rathmann, W.; Haastert, B.; John, J.; Lowel, H.; Holle, R.; Giani, G.: Cost-effectiveness of type 2 diabetes screening: results from recently published studies. Gesundheitswesen 67(Suppl 1), S167-S171 (2005)
9. Mobley, L.R.; Hoerger, T.J.; Wittenborn, J.S.; Galuska, D.A.; Rao, J.K.: Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med. Decis. Making 26(2), 194-206 (2006)
10. Schott, A.M.; Ganne, C.; Hans, D.; Monnier, G.; Gauchoux, R.; Krieg, M.A.; Delmas, P.D.; Meunier, P.J.; Colin, C.: Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos. Int. 18(2), 143-151 (2007)
11. Rubenstein, J.H.; Inadomi, J.M.; Brill, J.V.; Eisen, G.M.: Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin. Gastroenterol. Hepatol. 5(3), 312-318 (2007)
12. Shermock, K.M.; Gildea, T.R.; Singer, M.; Stoller, J.K.: Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis. COPD 2(4), 411-418 (2005)
13. Shenoy, A.U.; Aljutaili, M.; Stollenwerk, B.: Limited economic evidence of carotid artery stenosis diagnosis and treatment: a systematic review. Eur. J. Vasc. Endovasc. Surg. (2012). doi: 10.1016/j.ejvs.2012.08.010
14. Siebert, U.: When should decision-analytic modeling be used in the economic evaluation of health care? Eur. J. Health Econ. 4, 143-150 (2003)
15. Anderson, K.M.; Wilson, P.W.; Odell, P.M.; Kannel, W.B.: An updated coronary risk profile. A statement for health professionals. Circulation 83(1), 356-362 (1991)
16. Newcomb, P.A.; Carbone, P.P.: The health consequences of smoking. Cancer. Med. Clin. North Am. 76(2), 305-331 (1992)
17. Turner, D.; Raftery, J.; Cooper, K.; Fairbank, E.; Palmer, S.; Ward, S.; Ara, R.: The CHD challenge: comparing four cost-effectiveness models. Value Health 14(1), 53-60 (2011)
18. Ward, S.; Lloyd Jones, M.; Pandor, A.; Holmes, M.; Ara, R.; Ryan, A.; Yeo, W.; Payne, N.: A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11(14), 1-160, iii-iv (2007)
19. Munoz, N.; Bosch, F.X.; de Sanjose, S.; Herrero, R.; Castellsague, X.; Shah, K.V.; Snijders, P.J.; Meijer, C.J.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-527 (2003)
20. Swensen, S.J.; Jett, J.R.; Sloan, J.A.; Midthun, D.E.; Hartman, T.E.; Sykes, A.M.; Aughenbaugh, G.L.; Zink, F.E.; Hillman, S.L.; Noetzel, G.R.; Marks, R.S.; Clayton, A.C.; Pairolero, P.C.: Screening for lung cancer with low-dose spiral computed tomography. Am. J. Respir. Crit. Care Med. 165(4), 508-513 (2002)
21. Stollenwerk, B.; Gerber, A.; Lauterbach, K.W.; Siebert, U.: The German Coronary Artery Disease Risk Screening Model: development, validation, and application of a decision-analytic model for coronary artery disease prevention with statins. Med. Decis. Making 29(5), 619-633 (2009)
22. Kuntz, K.; Weinstein, M.: Modelling in Economic Evaluation. In: Drummond, M.F.; McGuire, A. (eds.) Economic evaluation in health care. Oxford University Press, Oxford (2001)
23. Briggs, A.; Karl, C.; Sculpher, M.: Decision modelling for health economic evaluation. Oxford University Press, Oxford (2006)
24. Assmann, G.; Cullen, P.; Schulte, H.: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105(3), 310-315 (2002)
25. Vrecer, M.; Turk, S.; Drinovec, J.; Mrhar, A.: Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int. J. Clin. Pharmacol. Ther. 41(12), 567-577 (2003)
26. Statistisches Bundesamt: Fachserie 12, Reihe 4. Gesundheitswesen. Todesursachen in Deutschland 2003. Statistisches Bundesamt, Wiesbaden (2005)
27. Stock, S.A.; Stollenwerk, B.; Redaelli, M.; Civello, D.; Lauterbach, K.W.: Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance. J. Women's Health (Larchmt) 17(3), 343-354 (2008)
28. Stolzenberg, H.: Bundes-Gesundheitssurvey 1998: Dokumentation des Datensatzes. Robert Koch Institut, Berlin (2000)
29. Lauterbach, K.W.; Wille, E.; Lüngen, M.; Stock, S.; Wendland, G.; Cischinsky, H.; Resch, S.: Modell eines fairen Wettbewerbs durch den Risikostrukturausgleich. Institut für Gesundheitsökonomie und klinische Epidemiologie (IGKE) der Universität zu Köln und Lehrstuhl für Volkswirtschaftslehre der Universität Mannheim, Köln, Mannheim. Gutachten im Auftrag des Verbandes der Angestellten-Krankenkassen e. V. (VdAK), des Arbeiter-Ersatzkassen-Verbandes e. V. (AEV), dem AOK-Bundesverband (AOK-BV) und dem IKK-Bundesverband (IKK-BV). In. (2001)
30. Daviglus, M.L.; Stamler, J.; Pirzada, A.; Yan, L.L.; Garside, D.B.; Liu, K.; Wang, R.; Dyer, A.R.; Lloyd-Jones, D.M.; Greenland, P.: Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA 292(13), 1588-1592 (2004)
31. Lowe, L.P.; Greenland, P.; Ruth, K.J.; Dyer, A.R.; Stamler, R.; Stamler, J.: Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch. Intern. Med. 158(18), 2007-2014 (1998)
32. Rosengren, A.; Dotevall, A.; Eriksson, H.; Wilhelmsen, L.: Optimal risk factors in the population: prognosis, prevalence, and secular trends; data from Goteborg population studies. Eur. Heart J. 22(2), 136-144 (2001)
33. Stamler, J.; Stamler, R.; Neaton, J.D.; Wentworth, D.; Daviglus, M.L.; Garside, D.; Dyer, A.R.; Liu, K.; Greenland, P.: Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 282(21), 2012-2018 (1999)
34. Stollenwerk, B.; Stock, S.; Siebert, U.; Lauterbach, K.W.; Holle, R.: Uncertainty assessment of input parameters for economic evaluation: Gauss's error propagation, an alternative to established methods. Med. Decis. Making 30(3), 304-313 (2010)
35. Dobson, A.J.: An Introduction to Generalized Linear Models. Chapman & Hall/CRC, London (2002)
36. Nelder, J.A.; Mead, R.: A simplex method for function minimization. Comput. J. 7(4), 308-313 (1965)
37. R Development Core Team: R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna (2010)
38. Efron, B.; Tibshirani, R.J.: An Introduction to the Bootstrap. Monographs on Statistics and Applied Probability, vol. 57. Chapman & Hall, New York (1993)
39. Klever-Deichert, G.; Gerber, A.; Stoller, J.K.; Lüngen, M.: Das deutsche Gesundheitswesen: Zahlen und rechtlicher Rahmen. In: Lauterbach, K.W.; Stock, S.; Brunner, H. (eds.) Gesundheitsökonomie: Lehrbuch für Mediziener und andere Gesundheitsberufe, pp. 75-104. Huber, Bern (2009)
40. Klever-Deichert, G.; Stollenwerk, B.; Gerber, A.; Wendland, G.; Lauterbach, K.: Gesundheitsökonomische Analyse der Prävention kardiovaskulärer Erkrankungen mit Lipidsenkern. In: Schwandt, P.; Parhofer, K.G. (eds.) Handbuch der Fettstoffwechselstörungen, pp. 1088-1101. Schattauer, Stuttgart (2006)
41. Statistisches Bundesamt: Preise. Verbraucherpreisindizes für Deutschland, Lange Reihen ab 1948. Statistisches Bundesamt, Wiesbaden (2012)
42. Zindel, S.; Stock, S.; Muller, D.; Stollenwerk, B.: A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv. Res. 12(1), 192 (2012)
43. Bilcke, J.; Beutels, P.; Brisson, M.; Jit, M.: Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med. Decis. Making 31(4), 675-692 (2011)
44. Kim, L.G.; Thompson, S.G.: Estimation of life-years gained and cost effectiveness based on cause-specific mortality. Health Econ 20(7), 842-852 (2011). doi: 10.1002/hec.1648
45. Hazen, G.; Li, Z.: Cohort decomposition for Markov cost-effectiveness models. Med. Decis. Making 31(1), 19-34 (2011)
46. Gnudi, S.; Sitta, E.; Lisi, L.: Relationship of body mass index with main limb fragility fractures in postmenopausal women. J. Bone Miner. Metab. 27(4), 479-484 (2009)
47. Zhao, L.J.; Liu, Y.J.; Liu, P.Y.; Hamilton, J.; Recker, R.R.; Deng, H.W.: Relationship of obesity with osteoporosis. J. Clin. Endocrinol. Metab. 92(5), 1640-1646 (2007)
48. Hill, A.V.: The combinations of haemoglobin with oxygen and with carbon monoxide. I. J. Physiol. 40, iv-vii (1910)
49. Weiss, J.N.: The Hill equation revisited: uses and misuses. FASEB J. 11, 835-841 (1997)
50. Brinton, L.A.; Hamman, R.F.; Huggins, G.R.; Lehman, H.F.; Levine, R.S.; Mallin, K.; Fraumeni Jr, J.F.: Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J. Natl Cancer Inst. 79(1), 23-30 (1987)
51. Thun, M.J.; Calle, E.E.; Namboodiri, M.M.; Flanders, W.D.; Coates, R.J.; Byers, T.; Boffetta, P.; Garfinkel, L.; Heath Jr, C.W.: Risk factors for fatal colon cancer in a large prospective study. J. Natl Cancer Inst. 84(19), 1491-1500 (1992)
52. Wasem, J.; Sroczynski, G.; Aidelsburger, P.; Buchberger, B.; Hessel, F.; Conrads-Frank, A.; Peters-Blochinger, A.; Kurth, B.M.; Wong, J.B.; Rossol, S.; Siebert, U.: Health economics of chronic infectious diseases: the example of hepatitis C. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49(1), 57-63 (2006)
53. Hagan, H.; Thiede, H.; Weiss, N.S.; Hopkins, S.G.; Duchin, J.S.; Alexander, E.R.: Sharing of drug preparation equipment as a risk factor for hepatitis C. Am. J. Public Health 91(1), 42-46 (2001)
54. Wright, J.C.; Weinstein, M.C.: Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 339(6), 380-386 (1998). doi: 10.1056/NEJM199808063390606
55. Sutton, A.J.; Abrams, K.R.; Jones, D.R.; Sheldon, T.A.; Song, F.: Methods for Meta-Analysis in Medical Research. Wiley, Chichester (2000)
56. Irwig, L.; Macaskill, P.; Glasziou, P.; Fahey, M.: Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 48(1), 119-130; discussion 131-132 (1995)
57. Moses, L.E.; Shapiro, D.; Littenberg, B.: Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat. Med. 12(14), 1293-1316 (1993)
58. Nease Jr, R.F.; Kneeland, T.; O'Connor, G.T.; Sumner, W.; Lumpkins, C.; Shaw, L.; Pryor, D.; Sox, H.C.: Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 273(15), 1185-1190 (1995)
59. Pignone, M.; Earnshaw, S.; Tice, J.A.; Pletcher, M.J.: Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann. Intern. Med. 144(5), 326-336 (2006)
60. Tsevat, J.; Goldman, L.; Soukup, J.R.; Lamas, G.A.; Connors, K.F.; Chapin, C.C.; Lee, T.H.: Stability of time-tradeoff utilities in survivors of myocardial infarction. Med. Decis. Making 13(2), 161-165 (1993)